Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-XT117 is a next-generation radiopharmaceutical therapy consisting of the beta-emitting radioisotope lutetium-177 conjugated to XT117, a fibroblast activation protein (FAP) antagonist. Developed initially by Sinotau Pharmaceutical Group, XT117 is designed to target FAP, which is highly expressed in the tumor stroma of various advanced solid tumors. The drug aims to deliver targeted cytotoxic radiation to the tumor microenvironment, leveraging the high affinity and prolonged intratumoral retention of the XT117 ligand. It is currently being evaluated in Phase 1 clinical trials for safety, dosimetry, and preliminary efficacy in patients with FAP-positive advanced solid tumors refractory to standard therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [177Lu]Lu-XT117.